Article info
PDFReview
Disease modification in multiple sclerosis: an update
- Correspondence to Dr Claire M Rice, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol BS16 1JB, UK; c.m.rice{at}bristol.ac.uk
Citation
Disease modification in multiple sclerosis: an update
Publication history
- First published October 7, 2013.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Update on disease-modifying therapies for multiple sclerosis
- Disease modifying therapies for relapsing multiple sclerosis
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Disease-modifying therapies for multiple sclerosis
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
- ▼Dimethyl fumarate for relapsing-remitting multiple sclerosis
- ▼Teriflunomide for multiple sclerosis